Application of reagents for detecting methylation levels of target regions in the FOXO6 gene in the preparation of bladder cancer diagnostic products
Through a kit to detect the methylation level of the target region of the FOXO6 gene, the problem of low sensitivity of existing bladder cancer diagnosis methods is solved, high-sensitivity bladder cancer detection is achieved, non-invasive diagnostic solutions are provided, and early screening is improved and diagnosis specificity.
Patent Information
- Application Number
- CN202210845857.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-07-19
AI Technical Summary
The existing bladder cancer diagnosis methods have the problem of low sensitivity, especially the detection of early tumors is difficult to meet clinical needs, and traditional methods have a high risk of suffering and complications to patients.
Develop a kit to detect the methylation level of the target region in the FOXO6 gene, using methylation-specific PCR, bisulfite sequencing, fluorescence quantitative PCR and other methods to detect methylation in bladder cancer patients through urine samples. , providing high sensitivity diagnostic solutions.
It has achieved non-invasive and highly sensitive bladder cancer diagnosis, improved the specificity of early screening and diagnosis, reduced the risk of pain and complications to patients, and is suitable for monitoring of people at high risk of bladder cancer.
Smart Images

Figure BDA0003752747490000061 
Figure BDA0003752747490000062 
Figure BDA0003752747490000071
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to an application of a reagent for detecting the methylation level of a target region in a FOXO6 gene in the preparation of a bladder cancer diagnosis product. Background Art
[0002] Bladder cancer is one of the most common malignant tumors of the urinary system, and its incidence rate is increasing year by year in my country. According to the tissue source, bladder cancer can be divided into bladder urothelial carcinoma, bladder squamous cell carcinoma, bladder adenocarcinoma, bladder sarcoma, etc. Among them, bladder urothelial carcinoma is the most common pathological type, accounting for more than 90% of all bladder cancer incidence. According to the treatment mode and disease prognosis, bladder cancer can be divided into non-muscle invasive disease (NMIBC) and muscle invasive disease (MIBC). The 5-year survival rate of bladder cancer is related to the stage of the disease at the time of diagnosis. The 5-year survival rate of carcinoma in situ is as high as 95.8%, while the 5-year survival rate of metastatic bladder cancer is as low as 4.6%. Although the cure rate of early bladder cancer is high, most patients are at risk of recurrence after transurethral resection, so bladder cancer monitoring is required after surgery. Early screening, early treatment and recurrence monitoring of bladder cancer are crucial to improving the survival rate of patients.
[0003] Currently, the main methods for diagnosing and postoperative monitoring of bladder cancer are cystoscopy and pathological biopsy. Although this method is the gold standard for diagnosing bladder cancer, cystoscopy can cause great pain to patients and there is a possibility of urethral perforation, bleeding or infection. Some non-invasive detection methods, such as urine exfoliative cytology and chromosome fluorescence in situ hybridization, have low sensitivity in diagnosing bladder cancer, especially early tumors, and cannot meet clinical needs. Therefore, a highly sensitive method for diagnosing bladder cancer is urgently needed.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] Based on this, the purpose of the present invention includes providing a reagent for detecting the methylation level of a target region in the FOXO6 gene for use in preparing a bladder cancer diagnostic product. The embodiment of the present invention uses a reagent for detecting the methylation level of a target region in the FOXO6 gene to prepare a bladder cancer diagnostic kit. The kit can detect bladder cancer with high sensitivity, providing a new technical solution for the screening and diagnosis of bladder cancer.
[0006] In a first aspect of the present invention, a reagent for detecting the methylation level of a target region in a FOXO6 gene is used in the preparation of a bladder cancer diagnosis product;
[0007] The target area includes area 1 or a part thereof defined as follows:
[0008] Using GRCh38.p14 as reference, region 1 is Chr1:41382214-41382419.
[0009] In some embodiments of the present invention, the partial area of area 1 is selected from one or more of area 2, area 3, area 4, area 5, area 6, area 7, area 8 and area 9 defined as follows:
[0010] Region 2 is the positive strand of Chr1:41382215-41382419,
[0011] Region 3 is the negative strand of Chr1:41382389-41382214,
[0012] Region 4 is the positive strand of Chr1:41382253-41382390,
[0013] Region 5 is the positive strand of Chr1:41382247-41382365,
[0014] Region 6 is the positive strand of Chr1:41382286-41382390,
[0015] Region 7 is the negative strand of Chr1:41382334-41382235,
[0016] Region 8 is the negative strand of Chr1:41382366-41382288, and
[0017] Region 9 is the negative strand of Chr1:41382316-41382217.
[0018] In some embodiments of the present invention, the reagent detects the methylation level of the target region by one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole genome methylation sequencing, pyrophosphate sequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and fluorescence quantification method.
[0019] In some embodiments of the present invention, the reagent includes a primer pair for detecting the methylation level of the target region, or further includes a detection probe for detecting the target region.
[0020] In some embodiments of the present invention, the reagent comprises a methylation primer pair and a non-methylation primer pair for detecting the methylation level of the target region having one or more of the following technical features:
[0021] The nucleotide sequences of the primer pair for detecting the methylation of region 2 are shown in SEQ ID NO.7 and SEQ ID NO.8.
[0022] The nucleotide sequences of the primer pair for detecting the non-methylated region 2 are shown in SEQ ID NO.9 and SEQ ID NO.10.
[0023] The nucleotide sequences of the primer pair for detecting the methylation of the region 3 are shown in SEQ ID NO.11 and SEQ ID NO.12, and,
[0024] The nucleotide sequences of the primer pair for detecting the non-methylated region 3 are shown in SEQ ID NO.13 and SEQ ID NO.14.
[0025] In some embodiments of the present invention, the reagent comprises a detection primer pair for detecting the methylation level of the target region and a detection probe corresponding to the detection primer pair having one or more of the following technical features:
[0026] The nucleotide sequences of the detection primer pair for detecting the region 4 are shown in SEQ ID NO.15 and SEQ ID NO.16, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.17.
[0027] The nucleotide sequences of the detection primer pair for detecting the region 5 are shown in SEQ ID NO.18 and SEQ ID NO.19, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.20.
[0028] The nucleotide sequences of the detection primer pair for detecting the region 6 are shown in SEQ ID NO.21 and SEQ ID NO.22, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.23.
[0029] The nucleotide sequences of the detection primer pair for detecting the region 7 are shown in SEQ ID NO.24 and SEQ ID NO.25, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.26.
[0030] The nucleotide sequences of the detection primer pair for detecting the region 8 are shown in SEQ ID NO.27 and SEQ ID NO.28, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.29, and
[0031] The nucleotide sequences of the detection primer pair for detecting the region 9 are shown in SEQ ID NO.30 and SEQ ID NO.31, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.32.
[0032] In some embodiments of the present invention, the reagent further comprises a detection primer pair for detecting an internal reference gene and a detection probe corresponding to the detection primer pair; optionally, the internal reference gene comprises the ACTB gene, and the ACTB gene corresponds to the detection primer pair shown in SEQ ID NO.33 and SEQ ID NO.34 and the detection probe shown in SEQ ID NO.35.
[0033] In some embodiments of the present invention, the sample to be detected includes a cell sample, a tissue sample or a urine sample.
[0034] In a second aspect of the present invention, a bladder cancer diagnosis kit is provided, comprising the reagent defined in the first aspect.
[0035] In some embodiments of the present invention, the diagnostic kit further comprises one or more of a sequencing reagent, an amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, and a DNA extraction reagent; optionally, the amplification reagent comprises an amplification buffer, dNTPs, a DNA polymerase, and Mg. 2+ One or more of .
[0036] Compared with the conventional technology, the present invention has the following beneficial effects:
[0037] The present invention prepares a test kit for detecting the methylation level of the target region in the FOXO6 gene. The test kit can detect bladder cancer with high sensitivity and has high specificity for detecting healthy human samples, providing a new technical solution for the screening and diagnosis of bladder cancer. In particular, the test kit can realize non-invasive diagnosis of bladder cancer, has excellent performance, and is expected to bring good news to people and patients at high risk of bladder cancer. DETAILED DESCRIPTION
[0038] The present invention will be further described in detail below in conjunction with the embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present invention more thorough and comprehensive. It should also be understood that the present invention can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various changes or modifications without violating the connotation of the present invention, and the equivalent form obtained also falls within the protection scope of the present application. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present invention. It should be understood that the present invention can be implemented without one or more of these details.
[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing implementation modes and embodiments and are not intended to limit the present invention.
[0040] the term
[0041] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0042] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0043] In the present invention, "plurality", "multiple", "multiple times", "multiple" and the like, unless otherwise specified, refer to a number greater than or equal to 2. For example, "one or more" means one or greater than or equal to two.
[0044] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.
[0045] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of the present invention, solve the technical problem of the present invention, and achieve the expected technical effect of the present invention.
[0046] Herein, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of the present invention.
[0047] In the present invention, “further”, “furthermore”, “particularly”, etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present invention.
[0048] In the present invention, "optionally", "optional", and "optional" mean optional, that is, any one of the two parallel solutions of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.
[0049] In the present invention, in the "first aspect", "second aspect", "third aspect", "fourth aspect", etc., the terms "first", "second", "third", "fourth", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0050] In the present invention, bladder cancer refers to cancer occurring on the bladder mucosa, and can be divided into urothelial (transitional) cell carcinoma, squamous cell carcinoma, adenocarcinoma, and some rare small cell carcinomas, mixed types, carcinosarcoma, or metastatic carcinoma, etc., according to its tissue type. Urothelial carcinoma accounts for more than 90% of bladder cancer.
[0051] In the present invention, diagnosis includes auxiliary diagnosis, recurrence risk assessment, assessment of cancer risk and cancer degree, prognosis and other aspects.
[0052] In the present invention, gene refers to a DNA segment encoding an amino acid polypeptide chain, which includes sequences located in the coding region and non-coding region that participate in gene transcription / translation and transcription / translation regulation.
[0053] In the present invention, the term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced in any way, including chemical synthesis, DNA replication, reverse transcription or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine and guanine.
[0054] In the present invention, methylation is a form of DNA chemical modification that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent binding of a methyl group to the 5th carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.
[0055] In the present invention, the methylation level refers to whether the cytosine in one or more CpG dinucleotides in a DNA sequence is methylated, or the frequency / ratio / percentage of methylation, which represents both a qualitative concept and a quantitative concept. In practical applications, different detection indicators can be used to compare DNA methylation levels according to actual conditions. For example, in some cases, the comparison can be made based on the Ct value of the sample test; in some cases, the proportion of gene methylation in the sample can be calculated, that is, the number of methylated molecules / (the number of methylated molecules + the number of non-methylated molecules) × 100, and then compared; in some cases, it is also necessary to statistically analyze and integrate the various indicators to obtain the final judgment indicator.
[0056] In the present invention, primer refers to an oligonucleotide that can be used in an amplification method (such as polymerase chain reaction PCR) to amplify a target sequence based on a polynucleotide sequence corresponding to a target gene or a portion thereof. Typically, at least one of the PCR primers used to amplify a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of the primer depends on many factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, oligonucleotide primers typically contain at least 10, 15, 20, 25 or more nucleotides, but may also contain fewer nucleotides, depending on the complexity of the target sequence. In the present disclosure, the term "primer" refers to a pair of primers that can hybridize with the double strands of a target DNA molecule or can hybridize with a region of a target DNA molecule that is located on both sides of the nucleotide sequence to be amplified.
[0057] In the present invention, Taqman probe refers to an oligonucleotide sequence containing a 5' fluorescent group and a 3' quenching group. When the probe binds to the corresponding site on the DNA, the probe will not emit fluorescence because of the presence of a quenching group near the fluorescent group. During the amplification process, if the probe binds to the amplified chain, the 5'-3' exonuclease activity of the DNA polymerase (such as Taq enzyme) will digest the probe, and the fluorescent group will be away from the quenching group, and its energy will not be absorbed, that is, a fluorescent signal will be generated. After each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment.
[0058] In the present invention, Sanger sequencing, i.e., first-generation sequencing, has a reaction system comprising: a target fragment, four deoxyribonucleotides (dNTPs), DNA polymerase, primers, etc., and four dideoxyribonucleotides (ddNTPs) labeled with different fluorescent groups need to be added. Since ddNTP lacks the 3'-OH group required for extension, the extended oligonucleotide is selectively terminated at G, A, T or C, and the four light wavelength signals are converted into computer-recognizable electrical signals through light excitation, and the target DNA sequence is determined according to the fluorescent signal of the last ddNTP incorporated in the reaction tube.
[0059] DNA methylation is a common way to regulate gene expression. Abnormal hypermethylation of cytosine in CpG dinucleotides of tumor suppressor genes may cause transcriptional silencing of genes and the occurrence of cancer. At present, hypermethylation of tumor suppressor genes has been considered an early event in the occurrence of bladder cancer. Therefore, changes in DNA methylation patterns can be used as a potential cancer screening, diagnosis and monitoring method. Since there are detached tumor cells and free DNA released by tumor cells in urine, the present invention believes that early diagnosis or monitoring of bladder cancer can be performed by detecting changes in the methylation levels of certain biomarkers in urine.
[0060] A first aspect of the present invention
[0061] The embodiment of the present invention provides a use of a reagent for detecting the methylation level of a target region in a FOXO6 gene in the preparation of a bladder cancer diagnosis product;
[0062] The target area includes area 1 or a part thereof defined as follows:
[0063] Using GRCh38.p14 as reference, region 1 is Chr1:41382214-41382419.
[0064] FOXO6 (forkhead box O6) gene, gene ID: 100132074, with reference to GRCh38.p14, its physical location is: Chr1: 41361434-41383590. It is predicted that this gene can bind to DNA and has transcription factor activity.
[0065] In some examples of the present invention, the partial area of area 1 is selected from one or more of area 2, area 3, area 4, area 5, area 6, area 7, area 8 and area 9 defined as follows:
[0066] Region 2 is the positive strand of Chr1:41382215-41382419,
[0067] Region 3 is the negative strand of Chr1:41382389-41382214,
[0068] Region 4 is the positive strand of Chr1:41382253-41382390,
[0069] Region 5 is the positive strand of Chr1:41382247-41382365,
[0070] Region 6 is the positive strand of Chr1:41382286-41382390,
[0071] Region 7 is the negative strand of Chr1:41382334-41382235,
[0072] Region 8 is the negative strand of Chr1:41382366-41382288, and
[0073] Region 9 is the negative strand of Chr1:41382316-41382217.
[0074] For example, the partial area of the area 1 is selected from any one of areas 2 to 9, or 2, 3, 4, 5, 6, 7, or 8 thereof.
[0075] Further, a partial area of the area 1 is area 6, area 7 or area 8. Further, a partial area of the area 1 is area 7.
[0076] It can be understood that the present invention does not particularly limit the method for detecting the methylation level, and the reagent can detect the methylation level of the target region by one or more of the following methods, but not limited to: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole genome methylation sequencing, pyrophosphate sequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and fluorescence quantitative method.
[0077] In some examples of the present invention, the reagent includes a primer pair for detecting the methylation level of the target region, or further includes a detection probe for detecting the target region.
[0078] In some examples of the present invention, the reagent includes a methylation primer pair and a non-methylation primer pair for detecting the methylation level of the target region having one or more of the following technical features:
[0079] The nucleotide sequences of the primer pair for detecting the methylation of region 2 are shown in SEQ ID NO.7 and SEQ ID NO.8.
[0080] The nucleotide sequences of the primer pair for detecting the non-methylated region 2 are shown in SEQ ID NO.9 and SEQ ID NO.10.
[0081] The nucleotide sequences of the primer pair for detecting the methylation of the region 3 are shown in SEQ ID NO.11 and SEQ ID NO.12, and,
[0082] The nucleotide sequences of the primer pair for detecting the non-methylated region 3 are shown in SEQ ID NO.13 and SEQ ID NO.14.
[0083] In some examples of the present invention, the reagent includes a detection primer pair for detecting the methylation level of the target region and a detection probe corresponding to the detection primer pair having one or more of the following technical features:
[0084] The nucleotide sequences of the detection primer pair for detecting the region 4 are shown in SEQ ID NO.15 and SEQ ID NO.16, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.17.
[0085] The nucleotide sequences of the detection primer pair for detecting the region 5 are shown in SEQ ID NO.18 and SEQ ID NO.19, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.20.
[0086] The nucleotide sequences of the detection primer pair for detecting the region 6 are shown in SEQ ID NO.21 and SEQ ID NO.22, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.23.
[0087] The nucleotide sequences of the detection primer pair for detecting the region 7 are shown in SEQ ID NO.24 and SEQ ID NO.25, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.26.
[0088] The nucleotide sequences of the detection primer pair for detecting the region 8 are shown in SEQ ID NO.27 and SEQ ID NO.28, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.29, and
[0089] The nucleotide sequences of the detection primer pair for detecting the region 9 are shown in SEQ ID NO.30 and SEQ ID NO.31, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.32.
[0090] In some examples of the present invention, the reagent further includes a detection primer pair for detecting an internal reference gene and a detection probe corresponding to the detection primer pair; optionally, the internal reference gene includes the ACTB gene, and the ACTB gene corresponds to the detection primer pair shown in SEQ ID NO.33 and SEQ ID NO.34 and the detection probe shown in SEQ ID NO.35.
[0091] In one example, the detection probe is labeled with a fluorescent reporter group and a fluorescent quencher group. The fluorescent reporter group is, for example, FAM, HEX, VIC, CY5, ROX, Texsa Red, JOE, Quasar 705, etc. The fluorescent quencher group is, for example, MGB, BHQ1, BHQ2, and BHQ3, etc.
[0092] It is understandable that the present invention does not impose any particular limitation on the type of sample for methylation level detection, and the sample may be selected from, but is not limited to, a cell sample, a tissue sample, or a urine sample.
[0093] Second aspect of the present invention
[0094] An embodiment of the present invention provides a bladder cancer diagnosis kit, comprising the reagent defined in the first aspect.
[0095] In some examples of the present invention, the diagnostic kit further comprises one or more of a sequencing reagent, an amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, and a DNA extraction reagent.
[0096] Optionally, the amplification reagent includes an amplification buffer, dNTPs, DNA polymerase and Mg 2+ One or more of .
[0097] The third aspect of the present invention
[0098] An embodiment of the present invention provides a method for diagnosing bladder cancer, the method comprising the following steps:
[0099] The diagnostic kit described in the second aspect is used to detect the methylation level of the subject's sample, and whether the subject has bladder cancer is determined based on the test results.
[0100] Compared with the conventional technology, the present invention has the following beneficial effects:
[0101] The present invention prepares a test kit for detecting the methylation level of the FOXO6 gene in the target region. The test kit can detect bladder cancer with high sensitivity and has high specificity for detecting healthy human samples, providing a new technical solution for the screening and diagnosis of bladder cancer. In particular, the test kit can realize non-invasive diagnosis of bladder cancer, has excellent performance, and is expected to bring good news to people and patients at high risk of bladder cancer. Specific embodiments
[0103] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0104] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0105] Example 1
[0106] Analyzing the methylation level of DNA in the Chr1:41382214-41382419 region (region 1) in the sample by bisulfite sequencing can effectively distinguish bladder cancer tissue from adjacent normal tissue. The specific testing process is as follows.
[0107] 1. Sample collection
[0108] A total of 96 cancer tissue samples and 96 corresponding adjacent normal tissue samples from patients diagnosed with bladder cancer by pathological examination were collected. All tissue samples were formalin-immersed and paraffin-embedded tissue samples. Among them, there were 42 non-muscle invasive cancer (NMIBC) tissue samples and 54 muscle invasive cancer (MIBC) tissue samples. The collection process of all tissue samples was approved by the ethics committee, all volunteers signed informed consent forms, and all tissue samples were anonymized.
[0109] 2. Sample DNA Extraction
[0110] QIAamp DNA FFPE Tissue Kit (Cat: 56404) was used to extract DNA from tissue samples, and the specific operations were carried out according to the instructions of the kit.
[0111] 3. Sample DNA conversion and purification
[0112] The kits used for conversion and purification of sample DNA are all nucleic acid conversion reagents from Wuhan Aimisen Life Science Technology Co., Ltd. (Ehan Medical No. 20200843). For specific operation steps, please refer to the kit instructions.
[0113] 4. PCR Amplification and Sequencing
[0114] After the DNA molecule is converted by bisulfite, the deamination of cytosine that does not undergo methylation is converted into uracil, and the methylated cytosine remains unchanged, and in the process of subsequent PCR amplification, uracil is all converted into thymine. It can be seen from this that after experiencing bisulfite conversion, the unmethylated cytosine in a single strand of the double-stranded DNA molecule is no longer complementary to the guanine in its original reverse complementary strand due to conversion into thymine, that is, the original positive strand and the original negative-sense strand of the converted DNA molecule are no longer fully complementary and paired, so it can be understood that when the positive strand and the negative-sense strand of the converted DNA molecule are carried out PCR amplification, the amplification primers used are different. Considering the specificity of primer binding, primer pairs are designed for the positive strand and the negative-sense strand of the DNA molecule in the Chr1:41382214-41382419 region, and the detection of methylation level is carried out.
[0115] Using the completely methylated sequence fragment converted by bisulfite and the completely unmethylated sequence fragment converted by bisulfite as templates, methylated primer pairs and non-methylated primer pairs were designed to amplify the corresponding positive and negative chain regions (the sequences of the amplicons are shown in Table 1), and the best ratio of the methylated primer pair and the non-methylated primer pair was screened to ensure that when the methylated primer pair and the non-methylated primer pair were added simultaneously in a PCR reaction system, when there was a methylated sequence greater than or equal to 1% in the template, a methylated product could be amplified, and only when the template was a non-methylated sequence fragment, the amplified product was a non-methylated product.
[0116] Table 1. DNA sequence of Chr1:41382214-41382419 region
[0117]
[0118] Using the transformed tissue sample DNA as a template, SEQ ID NO.7-SEQ ID NO.10 and SEQ ID NO.11-SEQ ID NO.14 in Table 2 as primer pairs, PCR reaction was performed to amplify the positive and negative strands of the DNA in the Chr1:41382214-41382419 region. The configuration system of the PCR reaction is shown in Table 3, and the DNA polymerase used in the system is PrimeSTAR HS DNA Polymerase (Takara, Cat: R010A). The PCR amplification procedure is the same as Table 4. After the PCR amplification is completed, the amplified product is subjected to Sanger sequencing (sent to a sequencing company) using a mixed primer (including a methylated primer pair and a non-methylated primer pair), and sequencing is performed from the 5' end and the 3' end at the same time.
[0119] Table 2. Methylation primer pairs and non-methylation primer pairs
[0120]
[0121]
[0122] Table 3. PCR reaction system
[0123] Components Dosage (μL) <![CDATA[10×buffer(Mg 2+ Free)]]> 5 <![CDATA[25mM Mg 2+ ]]> 4 dNTP Mix (10 mM each) 1 Methylated upstream primer (10 μM) 1 Methylated downstream primer (10 μM) 1 Unmethylated upstream primer (10 μM) 0.5 Unmethylated downstream primer (10 μM) 0.5 DNA polymerase 0.5 Template DNA 10 Ultrapure water Replenish to 50
[0124] Table 4. PCR reaction program
[0125]
[0126] 6. Results Analysis
[0127] The methylation status of the CpG sites in each amplicon of each sample was analyzed according to the sequencing peak graph. If the sequencing result of cytosine in the CpG dinucleotide is thymine, it is unmethylated; if the sequencing result of cytosine in the CpG dinucleotide is still cytosine, it is completely methylated; if the sequencing result of cytosine in the CpG dinucleotide contains both cytosine and thymine (double peak), it is partially methylated.
[0128] If more than 95% of the cytosine in the CpG dinucleotides in an amplicon is methylated (including complete methylation and partial methylation), the sample is considered to be methylation-positive in the amplified region; otherwise, the sample is considered to be methylation-negative in the amplified region. The number of methylation-positive and methylation-negative samples in the positive and negative chains of the Chr1:41382214-41382419 region of each type of tissue sample was calculated respectively; and the sensitivity and specificity of the detection were calculated, the sensitivity being the proportion of methylation-positive samples in samples with positive pathological results, and the specificity being the proportion of methylation-negative samples in samples with negative pathological results.
[0129] Table 5 shows the sensitivity and specificity of diagnosing bladder cancer tissue samples and adjacent tissue samples by detecting the methylation level of DNA molecules in the Chr1:41382214-41382419 region using the bisulfite sequencing method.
[0130] Table 5. Sensitivity and specificity of bisulfite sequencing for tissue samples
[0131]
[0132] As can be seen from Table 5, the methylation level of DNA molecules in the Chr1:41382214-41382419 region can be analyzed by bisulfite sequencing to effectively distinguish bladder cancer tissue samples from normal adjacent tissue samples, and the performance of diagnosing bladder cancer by analyzing the methylation level of the positive strand of DNA molecules in the Chr1:41382214-41382419 region is almost the same as that of the negative strand, which shows that this region is very suitable as a methylation molecular marker for diagnosing bladder cancer. Specifically, the sensitivity of the Chr1:41382214-41382419 region in diagnosing non-muscle invasive bladder cancer tissue samples is 73.81%-76.19%, and its sensitivity in diagnosing muscle invasive bladder cancer is 90.74%-92.59%, and its specificity in adjacent tissues is higher than 88%.
[0133] Example 2
[0134] In order to enhance the value of the kit in clinical applications, this embodiment provides a method based on fluorescent quantitative methylation-specific PCR (qMSP) to detect the methylation level of DNA molecules in the Chr1:41382214-41382419 region, and the methylation state of the sample can be judged according to the Ct value, and then whether the sample is a cancer sample. The method is simple, convenient, easy to operate, and the test report can be produced within half a working day. This embodiment provides an experimental process and detection effect for detecting the methylation level of the Chr1:41382214-41382419 region using the qMSP method to determine whether the tissue sample is a bladder cancer sample.
[0135] 1. The steps of sample collection, sample DNA extraction, transformation and purification are the same as those in Example 1.
[0136] 2.qMSP reaction
[0137] Six different pairs of detection primers and probes were designed using the fully methylated and bisulfite-converted sequence fragments SEQ ID NO.2 and SEQ ID NO.5 as templates, respectively, to perform methylation fluorescence quantitative PCR reactions. The nucleotide sequences of the primer pairs and detection probes are shown in Table 6, the sequences of the various target regions detected are shown in Table 7, and the methylated cytosine sites detectable by the primer pairs and detection probes are shown in Table 8.
[0138] Table 6. Nucleotide sequences of primer pairs and detection probes
[0139]
[0140] Table 7. Nucleotide sequences of target regions detected by each primer pair and detection probe
[0141]
[0142]
[0143] Table 8. Methylated cytosine sites detectable by primer pairs and detection probes
[0144]
[0145] The template DNA converted and purified by bisulfite was subjected to qMSP reaction to detect the methylation status of each sample to be tested in the Chr1:41382214-41382419 region, and each sample to be tested was amplified using the 6 detection primer pairs and detection probes in Table 8. In the process of PCR reaction, in a PCR tube, the necessary components such as reaction buffer, dNTP, DNA polymerase, template, etc. are first added; then the detection primer pair and detection probe (one of the 6 primer pairs and probe combinations) are added, and in addition, the detection primer pair and detection probe (SEQ ID NO.33-SEQ ID NO.35) of the internal reference gene ACTB are also added. The detection probe used here is a Taqman probe, the reporter group at the 5' end of the detection probe of the target region is FAM, and the quenching group at the 3' end is MGB, and the reporter group at the 5' end of the detection probe of the ACTB gene is VIC, and the quenching group at the 3' end is BHQ1. Invitrogen Platinum II Taq hot start DNA polymerase (Invitrogen, Cat: 14966005) was used for PCR amplification. The PCR reaction solution configuration system is shown in Table 9. PCR amplification was performed according to the amplification program shown in Table 10.
[0146] Table 9. qMSP reaction system
[0147] Components Specification Volume (μL) Platinum II PCR Buffer 5× 5 dNTPs 2.5mM each 3 Target region upstream primer 10μM 0.5 Target region downstream primer 10μM 0.5 Target area detection probe 10μM 0.5 ACTB upstream primer 10μM 0.5 ACTB downstream primer 10μM 0.5 ACTB detection probe 10μM 0.5 Taq enzyme / 0.5 DNA sample to be tested / 5 Purified water / Up to 25
[0148] Table 10. PCR reaction program
[0149]
[0150] Negative control and positive control: When using 6 different detection primer pairs and probes for detection, the negative control and positive control should be detected simultaneously. The negative control is TE buffer. The preparation method of the positive control is: artificially synthesize the sequence corresponding to the amplified region of ACTB after complete conversion by bisulfite, and clone it into a vector to form an artificial synthetic plasmid. Artificially synthesize the target region detected by the primer pairs numbered 3 to 8 and the detection probe (SEQ ID NO.37, 39, 41, 43, 45, 47), and clone them into a vector to form an artificial synthetic plasmid. The template DNA of the positive control tube is: 10 3 copies / μl of ACTB synthetic plasmid and 10 3 The positive control when the primer pair and probe 3 are used for amplification reaction is 10 3 copies / μl of ACTB synthetic plasmid and 10 3 The artificial synthetic plasmid containing SEQ ID NO.37 sequence was mixed in a 1:1 ratio of 1:1.
[0151] 3. PCR result analysis:
[0152] 1) Ct value reading: After PCR is completed, adjust the baseline, set the fluorescence value of the minimum Ct value of the sample in a PCR 1-2 cycles in advance as the baseline value, set the threshold at the inflection point of the S-type amplification curve, and obtain the Ct value of each gene in the sample.
[0153] 2) Quality control: The negative control should have no amplification, the positive control should have an obvious exponential growth period, and the Ct value of the positive control should be between 26-30. The Ct value of the internal reference gene of the sample to be tested should be ≤35. If the negative control, positive control and internal reference gene meet the above requirements, it indicates that this experiment is valid and the next step of sample result determination can be carried out. Otherwise, the experiment is invalid and must be retested.
[0154] 3) Result analysis and interpretation method: For tissue samples, if the Ct value of the sample to be tested in a certain detection area is ≤38, the sample is considered to be methylation-positive in this area; if the Ct value of the sample to be tested in a certain detection area is >38, the sample is considered to be methylation-negative in this area.
[0155] Table 11 shows the sensitivity and specificity of diagnosing bladder cancer tissue samples and adjacent tissue samples by detecting the methylation level of DNA molecules in the Chr1:41382214-41382419 region using the fluorescent quantitative methylation-specific PCR detection method.
[0156] Table 11. Sensitivity and specificity of tissue samples detected by qMSP
[0157]
[0158]
[0159] As can be seen from Table 11, the effect of using fluorescent quantitative methylation-specific PCR to detect the methylation level of DNA molecules in the Chr1:41382214-41382419 region to distinguish bladder cancer tissue samples and adjacent tissue samples is not inferior to the bisulfite sequencing method, and different primer pairs and probes designed for this region have good differentiation effects on cancer and adjacent tissue samples. Specifically, the sensitivity of the qMSP method for detecting non-muscle invasive bladder cancer tissue samples is above 71.43%, and can be as high as 78.57%. Its sensitivity for detecting muscle invasive bladder cancer tissue samples is higher than 90%, and its specificity for detecting adjacent tissues is higher than 86%.
[0160] Example 3
[0161] This example provides the performance of using the qMSP method to detect the methylation level of DNA molecules in the Chr1:41382214-41382419 region to distinguish urine samples from bladder cancer patients, healthy people, and patients with benign urinary system diseases.
[0162] 1. Sample collection
[0163] A total of 156 urine samples were collected from patients with bladder cancer diagnosed by pathological examination and 178 healthy people who underwent routine physical examinations, including 74 samples from patients with non-muscle invasive cancer and 82 samples from patients with muscle invasive cancer. In addition, 72 urine samples were collected from patients with common benign urinary system diseases (including glandular cystitis, urinary tract infection, prostatic hyperplasia, kidney stones, hydronephrosis, etc.). The volume of each urine sample collected was greater than 10 mL. The collection process of all samples was approved by the Ethics Committee, all volunteers signed informed consent forms, and all samples were anonymized.
[0164] 2. Sample DNA Extraction
[0165] The nucleic acid extraction kit of Wuhan Aimison Life Science Technology Co., Ltd. (Ehan Equipment No. 20210740) was used to extract DNA from urine samples. For specific steps, please refer to the kit manual.
[0166] 3. The transformation and purification of sample DNA are the same as in Example 1.
[0167] 4. The qMSP detection method is the same as in Example 2.
[0168] 5.qMSP results analysis
[0169] The reading and quality control of Ct value are the same as those in Example 2.
[0170] qMSP result analysis and interpretation method: For urine samples, if the Ct value of the sample to be tested in a certain detection area is ≤45, the sample is considered to be methylation-positive in this area, and if the Ct value of the sample to be tested in a certain detection area is >45, the sample is considered to be methylation-negative in this area. Using the qMSP detection method, the sensitivity and specificity of diagnosing urine samples of bladder cancer patients, healthy people and patients with benign urinary system diseases by detecting the methylation level of DNA molecules in the Chr1:41382214-41382419 region are shown in Table 12.
[0171] Table 12. Sensitivity and specificity of urine samples based on qMSP method
[0172]
[0173] As can be seen from Table 12, the performance of using the fluorescent quantitative methylation-specific PCR method to detect the methylation level of DNA molecules in the Chr1:41382214-41382419 region, and then distinguishing urine samples from bladder cancer patients, healthy people, and patients with benign urological diseases is good, and the effect trend is the same as that of detecting tissue samples. Different primer pairs and detection probes designed for this region have good distinguishing effects on urine samples from bladder cancer patients and non-cancer patients. The sensitivity of the qMSP method for detecting urine samples from patients with non-muscle invasive bladder cancer is higher than 70%; its sensitivity for detecting urine samples from patients with muscle invasive bladder cancer is higher than 89%; its total sensitivity for detecting bladder cancer is not less than 80%, and can reach up to 85.9%; its specificity for detecting urine samples from healthy people is higher than 92%; and its specificity for detecting urine samples from patients with benign urological diseases is higher than 87%. In addition, it can be seen that the primer pair and detection probe 6 have the best detection performance, and its total sensitivity for detecting urine samples from bladder cancer is as high as 85.9%. In summary, detecting the methylation level of DNA molecules in the Chr1:41382214-41382419 region can effectively improve the detection rate of early bladder cancer, thereby improving the quality of life and life cycle of bladder cancer patients.
[0174] On the whole, in order to solve the problem that there is no highly sensitive and highly specific method for screening or diagnosing bladder cancer at present, the embodiments of the present invention provide detection reagents and kits for diagnosing or assisting diagnosis of bladder cancer based on urine samples and tissue samples. The methylation level of the FOXO6 gene in the subject sample is detected by bisulfite sequencing or fluorescent quantitative methylation-specific PCR. If the methylation level of the FOXO6 gene in the subject sample is significantly higher than that in the healthy person's sample, the subject is considered to have bladder cancer. Specifically, by detecting the methylation level of the DNA molecule of the FOXO6 gene located in the Chr1:41382214-41382419 region in the urine sample, it is distinguished whether the patient has bladder cancer. The sensitivity of this method for diagnosing non-muscle invasive bladder cancer can reach up to 75.68%, and the sensitivity of its diagnosis of muscle invasive bladder cancer can reach up to 95.12%, and its specificity for detecting healthy human urine samples can reach 96.07%. This method has excellent detection performance and is non-invasive, which is expected to bring good news to people and patients at high risk of bladder cancer.
[0175] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0176] The above-described embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solution of the present invention in detail, but it cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present invention, several variations and improvements can be made, which all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of this application. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solution provided by the present invention through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the content of the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. Application of a reagent for detecting the methylation level of a target region in the FOXO6 gene in the preparation of a bladder cancer diagnostic product; The target area is a portion of area 1 defined as follows: Using GRCh38.p14 as reference, region 1 is Chr1:41382214-41382419; The partial area of area 1 is area 2, area 3, area 4, area 5, area 6, area 7, area 8 or area 9 defined as follows: Region 2 is the positive strand of Chr1:41382215-41382419, Region 3 is the negative strand of Chr1:41382389-41382214, Region 4 is the positive strand of Chr1:41382253-41382390, Region 5 is the positive strand of Chr1:41382247-41382365, Region 6 is the positive strand of Chr1:41382286-41382390, Region 7 is the negative strand of Chr1:41382334-41382235, Region 8 is the negative strand of Chr1:41382366-41382288, and Region 9 is the negative strand of Chr1:41382316-41382217; The reagents include a methylation primer pair and a non-methylation primer pair for detecting the methylation level of the target region as follows: The nucleotide sequences of the primer pair for detecting the methylation of region 2 are shown in SEQ ID NO.7 and SEQ ID NO.
8. The nucleotide sequences of the primer pair for detecting the non-methylated region 2 are shown in SEQ ID NO.9 and SEQ ID NO.
10. The nucleotide sequences of the primer pair for detecting the methylation of the region 3 are shown in SEQ ID NO.11 and SEQ ID NO.12, and, The nucleotide sequences of the primer pair for detecting the non-methylated region 3 are shown in SEQ ID NO.13 and SEQ ID NO.14; The reagent comprises the following detection primer pair for detecting the methylation level of the target region and a detection probe corresponding to the detection primer pair: The nucleotide sequences of the detection primer pair for detecting the region 4 are shown in SEQ ID NO.15 and SEQ ID NO.16, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.17; The nucleotide sequences of the detection primer pair for detecting the region 5 are shown in SEQ ID NO.18 and SEQ ID NO.19, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.20; The nucleotide sequences of the detection primer pair for detecting the region 6 are shown in SEQ ID NO.21 and SEQ ID NO.22, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.23; The nucleotide sequences of the detection primer pair for detecting the region 7 are shown in SEQ ID NO.24 and SEQ ID NO.25, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.26; The nucleotide sequences of the detection primer pair for detecting the region 8 are shown in SEQ ID NO.27 and SEQ ID NO.28, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.29; and The nucleotide sequences of the detection primer pair for detecting the region 9 are shown in SEQ ID NO.30 and SEQ ID NO.31, and the nucleotide sequence of the corresponding detection probe is shown in SEQ ID NO.
32.
2. The use according to claim 1, It is characterized in that The reagent detects the methylation level of the target region by one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray method, and methylation-specific high-resolution melting curve method.
3. The use according to claim 1, It is characterized in that The reagent also comprises a detection primer pair and a detection probe for detecting an internal reference gene.
4. The use according to claim 3, It is characterized in that The nucleotide sequences of the detection primer pair for detecting the internal reference gene are shown in SEQ ID NO.33 and SEQ ID NO.34, and the nucleotide sequence of the detection probe for detecting the internal reference gene is shown in SEQ ID NO.
35.
5. The use according to any one of claims 1 to 4, It is characterized in that The sample tested is a tissue sample or a urine sample.
6. A bladder cancer diagnostic kit, It is characterized in that Comprising the reagent defined in any one of claims 1 to 5.
7. The bladder cancer diagnostic kit according to claim 6, It is characterized in that The diagnostic kit also includes one or more of a sequencing reagent, an amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, and a DNA extraction reagent.
8. The bladder cancer diagnostic kit according to claim 7, It is characterized in that The amplification reagent includes an amplification buffer, dNTPs, DNA polymerase and Mg 2+ One or more of .
